Correlation between gastric carcinoma and ZAC gene-associated microsatellite instability and loss of heterozygosity

XIAO-YAN ZHU1*, JI-YAO YANG1*, YING HE2, GUO-HONG LIU1, YUN SUN1 and YI DING1

Departments of 1Histology and Embryology, and 2Cell Biology and Genetics, Basic Medical College, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China

Received February 1, 2016; Accepted March 17, 2017

DOI: 10.3892/ol.2017.6384

Abstract. The present study explored the association between loss of heterozygosity (LOH) or microsatellite instability (MSI) of the zinc finger regulator of apoptosis and cell-cycle arrest (ZAC) gene and the clinicopathological factors of gastric cancer. Samples of cancer and cancer-adjacent normal tissue from 30 patients with gastric cancer were collected. The genomic DNA was extracted from each and amplified with primers specific to ZAC microsatellite mutations, then run on a polyacrylamide gel for analysis. The CA197 microsatellite locus exhibited LOH in cancer sample 4. There was LOH in the 15AAAG locus in cancer sample 27 and cancer-adjacent tissue 23, and MSI at 15AAAG in cancer-adjacent tissue 27. There was MSI at the D6S1703 microsatellite locus in cancer-adjacent tissue 28. There was no LOH or MSI in the CA340 microsatellite locus in the gastric cancer or adjacent tissues analyzed. Thus, the frequency of LOH or MSI at ZAC gene-associated microsatellite loci for all patients was 13.3% (4/30). The present study has demonstrated that LOH and MSI events may contribute to the downregulation of ZAC; however, it is unlikely to be the primary cause, as it was only identified in 13.3% of cases.

Introduction

Zinc finger regulator of apoptosis and cell cycle arrest (ZAC) occurs within the chromosomal region 6q24. The zinc finger protein encoded by ZAC acts as a transcription factor, and there is substantial evidence for its role as a tumor suppressor (1). ZAC inhibits tumor cell proliferation through the induction of apoptosis and cell cycle arrest. ZAC has been implicated in tumorigenesis in a number of types of cancer; loss or downregulation of expression has thus far been identified in ovarian cancer (2), breast cancer (3), head and neck squamous cell carcinoma (4), nonfunctioning pituitary adenomas (5) and extra-skeletal myxoid chondrosarcoma (6). The molecular mechanism for the alteration in ZAC gene expression in gastric cancer tissues is unclear. Downregulation of tumor suppressor genes in cancer tissue may occur as the consequence of one or more genetic or epigenetic events. Genetic alterations include the mutation of the protein-coding region or loss of heterozygosity (LOH) and microsatellite instability (MSI) in the coding or non-coding regions. Epigenetic changes typically involve the methylation of promoter DNA or histone acetylation (7).

Microsatellite sequences are highly polymorphic, short tandem repeat sequences that occur in the human genome. They may be situated in the exon, intron or promoter regions. MSI is the polymorphism in the length of these microsatellite sequences; they may affect amino acid codons or the regulation of transcription (8). At present, various MSI phenotypes have been identified in a number of tumor types (7,8). The mechanism of inactivating mutations and deletions of both alleles of a tumor suppressor gene was involved in the process of carcinogenesis. Loss of heterozygosity (LOH) may increase cancer susceptibility, particularly following exposure to environmental carcinogens (9).

LOH or MSI can cause functional abnormality of the associated gene when they occur in protein coding regions, or lead to gene expression abnormalities in non-coding regions. In this study, four ZAC-associated microsatellite loci were selected for examination in gastric cancer tissues using a polymerase chain reaction (PCR)-PAGE-silver staining technique in order to explore LOH/MSI-associated mechanisms for the downregulation of ZAC expression in cancer. The association between LOH/MSI of the ZAC gene and clinicopathological factors in gastric cancer was also analyzed.

Patients and methods

Sample collection. Samples including cancer tissue, the tissue adjacent to cancer and normal gastric mucosal tissues, were collected from 30 patients with gastric cancer and preserved in liquid nitrogen. The gastric cancer samples were obtained from surgical patients of the Department of Gastroenterology, Cancer
Hospital of Henan (Zhengzhou, China). The gastric cancer tissues were collected from patients undergoing gastrectomy from March 2014 to December 2014. All patients were informed of the aims of specimen collection and provided written consent in accordance with the ethical guidelines of Cancer Hospital of Henan. The investigations were conducted according to the principles of the Declaration of Helsinki, and the Ethical Committee of Zhengzhou University approved the study.

Extraction of genomic DNA. Tissue from each sample (0.5 g) was ground and mixed with an equal amount of 2X Trition lysis mix. Following centrifugation (12,000 rpm, 5 min, 4°C), the sediment was incubated with EDTA-Na$_2$ proteinase K-SDS mixture. It was treated three times with phenol, phenol-chloroform-isoamyl alcohol mixture and chloroform-isoamyl alcohol mixture in sequence, respectively. The DNA product was precipitated with anhydrous isopropanol and dissolved in Tris-EDTA buffer. It was then stored at -20°C. The integrity of genomic DNA was evaluated by 1% agarose gel electrophoresis, and the purity was determined using the A$_{260}$/A$_{280}$ absorbance value measured with a spectrophotometer.

PCR reaction. Based on the sequences of the ZAC-associated microsatellite loci CA197, 15AAAG, CA340 and D6S1703 as reported in GenBank (Gene ID: 5325; PMID:11313869; DOI: 10.1038/sj.onc.1204237), four pairs of PCR primers were designed using Primer3 online primer design software (Primer 3 Input 0.4.0 http://frodo.wi.mit.edu/). The PCR reactions were performed in the corresponding reaction systems, consisting of 10 µl 2X Taq PCR Mastermix (Shanghai Sangon Biological Engineering Technology & Services Co., Ltd., Shanghai, China), 0.9 µl forward primer, 0.9 µl reverse primer, 1 µl template DNA (50 ng/µg) and 7.2 µl water. The PCR products were run on 2% agarose gel electrophoresis for 45 sec, followed by a final extension step of 72°C for 7 min.

CA197. For the detection of CA197 (CA)$_n$ fragments, the following primers were used: Forward, TTATATGTTCGATTTCCTTT; reverse, CAAAACATGGGCACACATATACC. PCR conditions were as follows: 95°C for 5 min followed by 38 cycles of 95°C for 30 sec, annealing at 52°C for 30 sec and extension at 72°C for 45 sec, followed by a final extension step of 72°C for 7 min.

15AAAG. For the detection of 15AAAG (CTT)$_n$ fragments, the following primers were used: Forward, CCTCACCTGCGTTTGTGC; reverse, GGTGACAGAAGACACCCAAC. PCR conditions: 95°C for 5 min followed by 35 cycles of 95°C for 30 sec, annealing at 58°C for 30 sec and extension at 72°C for 45 sec, followed by a final extension step of 72°C for 7 min.

CA340. For the detection of CA340 (AT)$_n$ fragments, the following primers were used: Forward, AGAGTTTGCAGTTGACCAAGAT; reverse, TCTCCTACCTCCCTTTCATCC. PCR conditions: 95°C for 5 min followed by 42 cycles of 95°C for 30 sec, annealing at 54°C for 30 sec and extension at 72°C for 45 sec, followed by a final extension step of 72°C for 7 min.

D6S1703. For the detection of (CA)$_n$ fragments, the following primers were used: Forward, CTGGTGGCTGTGATATCCA AAAT; reverse, TTTGGAGGATCAGGAAAGAAAA. PCR conditions: 95°C for 5 min followed by 35 cycles of 95°C for 30 sec, annealing at 55°C for 30 sec and extension at 72°C for 45 sec, followed by a final extension step of 72°C for 7 min.

Determination of MSI and LOH. The PCR products were run on a 6% polyacrylamide gel at 550V for 2.5 h. Following electrophoresis, the gel was fixed with 10% ethyl alcohol for 10 min at room temperature. The gel was oxidized with nitric acid for 2 min and stained with silver nitrate solution 15 min at room temperature. Sodium carbonate-formaldehyde solution was added to color the gel 3 times, then the staining reaction was terminated through the addition of acetic acid (10%) at room temperature. If the density of a band was not present or lowered to that of that of 50% of normal tissue, it was defined as LOH. If the density of the band was more than that of normal tissue, it was defined as MSI.

Results

CA197. The amplified (CA)$_n$ fragment size was 240 bp (Fig. 1A). A single LOH event was observed at this locus in the tumor tissue from case 4, equating to an incidence of 3.3% (1/30; Fig. 1B). There were no incidences of MSI at this locus in the cancer tissue samples, or incidences of LOH or MSI in the cancer-adjacent tissue.

15AAAG. The amplified (CTT)$_n$ fragment size was 173 bp (Fig. 2A). There was a single LOH event at this locus in sample 27, an incidence of 3.3% (1/30; Fig. 2B). No incidences of MSI were detected at this locus in the cancer tissue; however, cancer-adjacent tissue from sample 27 exhibited MSI at this locus (incidence, 3.3%; Fig. 2B). In the cancer-adjacent tissue of case 23 there was one LOH event at this locus (incidence, 3.3%; Fig. 2C).

D6S1703. The amplified (CA)$_n$ fragment length was 223 bp (Fig. 3A). In the cancer-adjacent tissue of one case (case 28) an MSI event was detected (incidence, 3.3%; Fig. 3B). No other MSI or microsatellite LOH events were detected at this locus in any tissue.

CA340. The amplified (AT)$_n$ fragment length was 247 bp (Fig. 4). No cancer or cancer-adjacent tissue samples exhibited MSI or LOH at this locus.

Association between MSI/LOH and clinicopathological variables. As presented in Table II, all four cases of moderately-differentiated gastric cancer were negative for MSI/LOH. In the 26 cases of poorly-differentiated gastric cancer, 4 cases were MSI/LOH positive (Table I), including 1 case at clinical stage I/II and 3 cases at stage III/IV. These were staged according to the tumor-node-metastasis classification system and graded into five groups [the TNM classification UICC 2009, 7th edition (10)]; Stage 0 (TisN0M0, n=0), Stage I (T1N0-1M0, T2N0M0, n=8), Stage II (T1N2-3M0, T2N1-2M0, T3N0M0, T4aN0M0, n=64), Stage III (T2N3M0, T3N2-3M0, T4aN1-3M0, T4bN0-3M0, n=73), Stage IV (TanyNanyM1, n=8).
ZAC expression has previously been identified to be downregulated or eliminated in a variety of solid cancer types, including breast (3), ovarian (2,11,4), head and neck squamous cell carcinoma (4), pheochromocytoma (12) and pituitary adenoma (5). Differences in the frequency of ZAC gene LOH in the tumor lead to the downregulation of ZAC (13). In previous reports, the frequency of ZAC gene LOH in ovarian (11), breast (3) and squamous cell carcinoma (4) tumors was 36.4, 40 and 31.4%, respectively; in B-cell lymphoma, LOH was identified in 23% (3/11) of cases (8). Screening in colorectal cancer revealed an LOH for at least one marker in half of the cases, but no mutations in the ZAC coding region (14). Including all 6q23-25 ZAC-specific microsatellite markers, which differ to those used in the present study. LOH or allele imbalance was detected in 50% (9/18) of pheochromocytomas (5). In the present study, microsatellite LOH or MSI occurred in 13.3% (4/30) of gastric cancer cases, demonstrating that ZAC gene microsatellite LOH/MSI may be one of the molecular mechanisms underlying ZAC gene downregulation in gastric cancer tissue.

ZAC is a maternally imprinted gene (12). If the paternal allele were lost, ZAC gene expression would not be influenced; if the maternal allele were lost, ZAC gene expression would be silenced, causing ZAC downregulation (12,13). However, it was not possible to check which allele was lost in the present study. A study by Jarmalaite et al (12) demonstrated that the rate of ZAC gene expression in gastric cancer was 33.3%, markedly below the 66.6% of normal gastric mucosa tissues. A LOH/MSI frequency of 13.3%, as identified in the present study, would be insufficient to explain the low levels of ZAC gene expression in gastric cancer, as observed in the study by Jarmalaite et al (12). The study further determined that that 29.5% of gastric cancer samples exhibited ZAC promoter

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Patients, n</th>
<th>ZAC MSI/LOH cases, n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>24</td>
<td>4</td>
</tr>
<tr>
<td>Female</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;60</td>
<td>18</td>
<td>2</td>
</tr>
<tr>
<td>≥60</td>
<td>12</td>
<td>2</td>
</tr>
<tr>
<td>Tumor diameter</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;5 cm</td>
<td>16</td>
<td>2</td>
</tr>
<tr>
<td>≥5 cm</td>
<td>14</td>
<td>2</td>
</tr>
<tr>
<td>Histopathological classification</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderately differentiated</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Poorly differentiated</td>
<td>26</td>
<td>4</td>
</tr>
<tr>
<td>Clinical stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I or II</td>
<td>14</td>
<td>1</td>
</tr>
<tr>
<td>III or IV</td>
<td>16</td>
<td>3</td>
</tr>
</tbody>
</table>

ZAC, zinc finger regulator of apoptosis and cell-cycle arrest.

Table I. ZAC-associated MSI and LOH events detected in 30 paired cancer and cancer-adjacent tissue samples from patients with gastric cancer.

<table>
<thead>
<tr>
<th>Tissue</th>
<th>CA197</th>
<th>15AAAG</th>
<th>D6S1703</th>
<th>CA340</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer tissue, n</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Adjacent tissue, n</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>LOH</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>MSI</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>

ZAC, zinc finger regulator of apoptosis and cell-cycle arrest; MSI, microsatellite instability; LOH, loss of heterozygosity.

Discussion

A study by Jarmalaite et al (12) demonstrated that the rate of ZAC gene expression in gastric cancer was 33.3%, markedly below the 66.6% of normal gastric mucosa tissues. A LOH/MSI frequency of 13.3%, as identified in the present study, would be insufficient to explain the low levels of ZAC gene expression in gastric cancer, as observed in the study by Jarmalaite et al (12). The study further determined that that 29.5% of gastric cancer samples exhibited ZAC promoter
methylation and that a high rate ZAC promoter methylation is associated with the loss of ZAC expression in gastric cancer tissue (12). Therefore, in gastric cancer tissue, alterations to ZAC function may be a result of genetic and epigenetic modifications.

A high rate of MSI has been associated with the development of multiple primary colorectal carcinomas (14). The rate of MSI has also been demonstrated to be associated with gastric cancer clinical pathology (15). A previous study revealed that MSI events in gastric cancer were more likely in women and with increasing age, and that they were associated with poor tumor differentiation (16). Another study reported that MSI was not associated with any index of clinical pathology in familial gastric cancer, whereas MSI was more likely in women and with increasing age, and was associated with the intestinal subtype in sporadic gastric cancer (17). A further study of gastric cancer by Seo et al (18) identified associations between a high MSI frequency and increasing age, tumor size and intestinal subtype. Another previous study demonstrated that the rate of LOH in p16 microsatellite loci did not significantly differ between gastric cancer tumors with moderate and poor levels of differentiation (19).

The present study has demonstrated that LOH and MSI events may contribute to the downregulation of ZAC; however, it is unlikely to be the primary cause, as it was only identified in 13.3% of cases. In the present study, all four patients exhibiting MSI/LOH were male with a poorly-differentiated adenocarcinoma, including three cases of stage III-IV and one case of stage I-II, suggesting a trend between MSI/LOH occurrence and poorly-differentiated, advanced-stage tumors. However, the low number of participants, including just four...
female patients and four moderately-differentiated tissue specimens, limits the present study. In order to determine whether ZAC gene-associated LOH/MSI is associated with sex, tumor differentiation and clinical stage in gastric cancer, further studies with a larger sample size are required. In order to explore the underlying mechanism of ZAC gene downregulation in gastric cancer, our future study will aim to detect the methylation of the ZAC gene promoter, and the levels of ZAC mRNA and protein expression, and to analyze the relationship between methylation, MSI/LOH and ZAC gene expression.

References